1. Introduction {#sec1-cancers-12-02055}
===============

Gastric cancer (GC), the third leading cause of cancer death globally \[[@B1-cancers-12-02055]\] and the seventh leading cause of cancer death in Taiwan in 2018, is one of the most widespread cancers, particularly in East Asia \[[@B2-cancers-12-02055]\]. Although the incidence of GC has been declining, it remains a fatal disease. Recently, there has been an upward trend of GC incidence among young patients, especially in the Chinese population \[[@B3-cancers-12-02055]\], and a less remarkable decline among women than in men \[[@B4-cancers-12-02055]\]. Each year, approximately 4000 people are diagnosed with GC, and the standard incidence rate is 9.5 cases per 100,000 person-years in Taiwan \[[@B5-cancers-12-02055]\].

Approximately 85--90% of GC cases are due to adenocarcinomas \[[@B6-cancers-12-02055]\]. The etiology of GC is related to diet, *Helicobacter pylori* infection, and the environment \[[@B7-cancers-12-02055]\]. According to the American Joint Committee on Cancer (AJCC), GC is staged into four groups based on tumor, node, and metastasis (TNM) classification. The cancer stage determines the treatment protocol and prognosis. GC is difficult to detect in the early stages because the disease usually progresses gradually in the beginning; thus, there is often a delay in the diagnosis \[[@B8-cancers-12-02055]\].

Surgery, chemotherapy, and radiotherapy are the conventional treatments for GC. Surgical resection and chemotherapy are the first-line therapies for GC. Radiotherapy, immunotherapy, target therapy, and hyperthermic intraperitoneal chemotherapy (HIPEC) are often administered as adjuvant therapy in the advanced stage \[[@B9-cancers-12-02055]\]. The treatment of GC stages Ib, II, and III mainly comprises first-line surgery and subsequent adjuvant chemotherapy. Stage Ia with favorable prognosis can be treated simply with surgery without any other treatment, whereas stage IV with very poor prognosis is treated with chemotherapy as a first-line treatment, usually accompanied by other neoadjuvant or adjuvant therapies \[[@B10-cancers-12-02055],[@B11-cancers-12-02055]\]. More than half of patients with GC are at stages Ib, II, and III, and surgery and chemotherapy are the most common treatments in Taiwan \[[@B5-cancers-12-02055]\]. The recurrence rate after GC surgery is 40%, which is reduced to 13% when accompanied by chemotherapy. The five-year survival rate for patients with GC varies based on the cancer stage and population characteristics \[[@B12-cancers-12-02055]\]. It is less than 40% in most countries and 60--69% in Japan and South Korea \[[@B13-cancers-12-02055]\]. Generally, the five-year survival rate after treatment is 55% in Taiwan \[[@B5-cancers-12-02055]\]. Therefore, developing strategies to effectively enhance the survival of patients with GC is critical.

Statins, which can significantly decrease plasma cholesterol levels, are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. It has been confirmed that statins can lower mortality and morbidity in cardiovascular diseases, and they are often used to treat hypercholesterolemia \[[@B14-cancers-12-02055]\]. The anticancer mechanisms of statins involve the inhibition of angiogenesis, inflammation, immunomodulation, and others \[[@B9-cancers-12-02055]\]. In GC cell lines, statins can decrease the level of cellular cholesterol \[[@B15-cancers-12-02055]\], suppress genes involved in cell division, and activate apoptosis \[[@B16-cancers-12-02055]\]. Additionally, animal model studies have shown that statins, combined with radiotherapy or chemotherapy, can reduce tumor volumes \[[@B17-cancers-12-02055]\]. However, clinical studies on this topic are limited. Some previous case--control studies have verified that patients who used statins exhibited a reduced risk of GC \[[@B15-cancers-12-02055],[@B18-cancers-12-02055]\]. Few studies have investigated how statin use improves survival and outcomes after GC diagnosis. One study observed a 17% decrease in the cancer-related death in the United Kingdom \[[@B19-cancers-12-02055]\], and another study revealed an 83% decrease in all-cause mortality after six months of statin use in Korea \[[@B20-cancers-12-02055]\].

Studies have assessed the antitumor and chemopreventive role of statins; nevertheless, the effects of statin use on mortality in patients with GC after treatments remain unclear. This nationwide population-based research investigates the relationship between statin use and the overall survival (OS) of patients with GC after surgery and adjuvant chemotherapy in Taiwan.

2. Results {#sec2-cancers-12-02055}
==========

In this analysis, a total of 10,617 patients with GC were included out of the one million randomly sampled patients. We identified 472 (4.4%) patients who used statins and 10,145 (95.6%) patients who were statin non-users during 1999--2008. After propensity score (PS) matching at a ratio of 1:4, there were 367 and 1468 statin users and non-users, respectively ([Figure 1](#cancers-12-02055-f001){ref-type="fig"}).

The characteristics of the study cohort are summarized in [Table 1](#cancers-12-02055-t001){ref-type="table"}. The mean age of both statin users and non-users was 64 years. No significant difference was observed between the baseline characteristics of statin users and non-users, except that statin non-users received more triglyceride-lowering drugs. The number of GC patients that died with and without statin use was 138 (37.6%) and 895 (61.0%), respectively.

[Figure 2](#cancers-12-02055-f002){ref-type="fig"} illustrates the outcomes of the Kaplan--Meier analysis for the matched cohort. The OS improvement showed a progressive dose--response relationship in the matched cohort. The log-rank test revealed a significant increase in the OS (*p* \< 0.001, as per the Kaplan--Meier curve) of patients with GC.

[Table 2](#cancers-12-02055-t002){ref-type="table"} indicates the dose--response relationship between statin use and the OS of patients with GC after surgery and adjuvant chemotherapy. The adjusted hazard ratios (HRs) were 0.62 (95% confidence intervals (CI), 0.50--0.78) and 0.34 (95% CI, 0.26--0.45) for GC patients with a statin use of 28--167 cumulative defined daily doses (cDDDs) and \>168 cDDDs, respectively. Sensitivity analysis showed that statin use had a small effect on the OS of patients with GC in different models with related comorbidities, chemotherapy regimen, and other medicines. This outcome was found to be consistent after excluding some factors causing significant heterogeneity. Sensitivity analysis also demonstrated that the dose--response association between statin use and OS remained in different subgroups of gender and age.

3. Discussion {#sec3-cancers-12-02055}
=============

To the best of our knowledge, our study is the first broad random nationwide research to examine the dose--response relationship between statin use and the OS of patients with GC after surgery and adjuvant chemotherapy in Taiwan. This study was controlled for the confounding effects of age, gender, urbanization, income, comorbidities, chemotherapy regimen, and other medicines. The study period was 1999--2008, and the follow-up time was until 31 December 2013. Our subpopulation analysis revealed that the use of statins reduced the mortality in these cohorts. The risk of the death for statin users and statin non-users was 37.6% and 61.0%, respectively, during the study period. After controlling for potential confounders, as the cumulative dose of statins increased a significant tendency towards reducing GC mortality was observed.

We identified the cohort from a population-based and high-quality historical computerized database, which included all the GC patients' demographic and medical information during the study period. Thus, the possibility of selection and recall bias was eliminated. The study also had a substantial cohort size and a long follow-up period. Moreover, to examine whether the outcomes were consistent, sensitivity analyses were performed with stratification to clarify potential confounders. Especially comorbidities and chemotherapy regimen, which may affect the outcome and prognosis of GC \[[@B20-cancers-12-02055]\], were considered important confounders and examined in this study. No significant changes were observed in the HRs of our measured outcomes in different subgroups.

Statins, which mainly prevent the risk of cardiovascular and cerebrovascular diseases and reduce serum cholesterol levels clinically, are inhibitors of HMG-CoA reductase \[[@B14-cancers-12-02055]\]. Various previous in vitro and in vivo studies have confirmed the antitumor effects of statins on GC. Several potential anticancer mechanisms have been investigated. The basic mechanism of the anticancer effect of statins involves the rate-limiting enzyme in mevalonate synthesis and the inhibition of HMG-CoA reductase, leading to decreased activity of the RAS protein involved in cellular proliferation, differentiation, angiogenesis, and anti-apoptosis \[[@B21-cancers-12-02055],[@B22-cancers-12-02055]\]. An experimental study showed that the use of simvastatin decreased cholesterol levels in the epithelial cells of the stomach and reduced the translocation and phosphorylation of *H. pylori* cytotoxin-associated gene A (CagA), which is considered to play a main role in GC development \[[@B15-cancers-12-02055]\]. Moreover, Histone deacetylase 2 (HDAC2) was proven to be overexpressed in GC. Recent studies have demonstrated that lovastatin can suppress HDAC2 expression by binding to areas near HDAC2 active sites, and HDAC2 inhibition induces the apoptosis of GC cells. Lovastatin has also been found to inhibit the growth of GC cells in vitro in a dose-dependent manner \[[@B23-cancers-12-02055]\]. The results of our research are consistent with the hypothesis concerning the actions of statins.

The chemopreventive effects of statins on GC have been widely discussed in many countries, especially in East Asian countries such as Japan, Korea, and Taiwan, where the GC incidence rate is the highest. Several studies have shown 30--35% reductions in GC risk with statin use \[[@B15-cancers-12-02055],[@B18-cancers-12-02055],[@B22-cancers-12-02055],[@B24-cancers-12-02055]\]. However, only a few observational and clinical research studies have investigated the survival rate of GC patients using statins. Little evidence of progression-free survival or OS difference between statin users and placebo users was noticed \[[@B20-cancers-12-02055],[@B25-cancers-12-02055],[@B26-cancers-12-02055]\]. Poor prognosis of the study-selected advanced GC patients may be the reason why slight significant differences were observed between the overall survival of statin users and statin non-users. A Korean study that examined all-cause mortality and recurrence-free survival in 241 patients with stage II and III GC undergoing radical gastrectomy has provided some evidence. All-cause mortality (HR 0.17; 95% CI, 0.03--0.88) and recurrence-free survival (HR 0.37; 95% CI, 0.10--1.37) in long-term statin users who had been administered statins for more than 6 months were more positive than in short-term users (\<6 months) \[[@B20-cancers-12-02055]\]. Another independent UK cohort study demonstrated decreased cancer-specific mortality (adjusted HR 0.83; 95% CI, 0.74--0.92) in GC patients with statin use \[[@B19-cancers-12-02055]\]. In our study, a notable dose--response relationship was observed between statin use and the OS of patients with GC post surgery and adjuvant chemotherapy. The adjusted HRs were 0.62 (95% CI, 0.50--0.78) and 0.34 (95% CI, 0.26--0.45) for statin users with 28--167 cDDDs and \>168 cDDDs, respectively. The difference may have been due to practical issues such as different stages of GC, varied patient populations, uneven research duration, or categories of statin exposure \[[@B27-cancers-12-02055]\]. The sample size and the duration of follow-up affected the outcomes. Nonetheless, the survival benefits of statin use for patients with GC after surgery and adjuvant chemotherapy were confirmed in Taiwan, consistent with the result in Asian and Western populations.

This study also has several limitations. First, statin users might not have fully followed the prescribed dosage; however, improvements in the OS of patients with GC following statin use were observed. Second, National Health Insurance (NHI) does not reimburse over-the-counter statin prescriptions, which might have resulted in an underestimation. However, this influence was minimal because only a small number of patients purchase this medicine by themselves. Third, because only the date of death, but not the cause of death, was recorded by the Registry of Catastrophic Illness Patients Database (RCIPD) of National Health Insurance Research Database (NHIRD), the effects of statins on patients with GC who died of a different cause could not be analyzed. Fourth, some potential confounders, including body mass index, smoking and drinking status, which might be associated with the survival of GC patients, were not included in our database. We used alcoholism, smoking-related disorder, diabetes mellitus, hypertension, chronic kidney disease, and liver cirrhosis as additional covariates in the sensitivity analyses. No obvious confounding effects were found because the estimates did not change significantly. Finally, we could not determine the stage of GC from the NHIRD, but we could speculate the stage of GC patients from their treatment protocol. The clinical practice guideline was made by medical experts, according to Taiwan NHI payment regulations.

4. Materials and Methods {#sec4-cancers-12-02055}
========================

4.1. Data Source {#sec4dot1-cancers-12-02055}
----------------

The current research employed the Taiwan NHIRD, which included the RCIPD. By the end of 2010, nearly 23.7 million Taiwanese people (i.e., 99% of the country's population) were insured under the NHI Program implemented in 1995 \[[@B28-cancers-12-02055]\]. The RCIPD enrolls every patient affected by catastrophic illness that was confirmed through imaging, laboratory, pathology, and clinical diagnosis by NHI Administration experts. The dataset comprises the medical records and information of patients, such as age, gender, date of birth, medical care facilities and specialties, date of outpatient clinical visits or admission, management, procedures and treatment, prescription drugs (name, dosage, and duration), identification number of transfer, and three major diagnoses according to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Therefore, the NHIRD provides the best platform for epidemiologic research.

Electronic information or patient identity and organization, was encrypted to protect patient privacy. Thus, the informed consent record of patients were not required in our study. The Ethics Review Board of Chang Gung Memorial Hospital, Chia-Yi Branch, Taiwan (201901743B0C501), approved this study on 9 April 2020.

4.2. Study Population {#sec4dot2-cancers-12-02055}
---------------------

Patients newly diagnosed with GC (ICD-9-CM code 151) from 1999 to 2008 who were older than 18 years from RCIPD of Taiwan comprised the study cohort. Patients with GC who had not undergone surgery, chemotherapy, or chemotherapy before surgery were excluded from our cohort. We tracked the study cohort until 31 December 2013, or the date of death. Patients with any other cancer diagnosed before GC and those with incomplete data were also excluded.

The statin prescriptions for this study cohort were collected from RCIPD from the surgery date of patients newly diagnosed with GC during the study period, to the date of death or the end of follow-up. The total exposed dosage, cDDD \[[@B29-cancers-12-02055]\], was used to compare the sum of dispensed DDD of statin usage with the OS of patients with GC. In the study population, patients treated with more than 28 cDDDs of statins after the date of the GC surgery were defined as statin users, whereas those treated with less than 28 cDDDs were defined as statin non-users. We also classified statin users into two groups (28--67 cDDDs and \>167 cDDDs) to observe the dose--effect relationship in comparison with statin non-users.

4.3. Study Variables {#sec4dot3-cancers-12-02055}
--------------------

The demographic characteristics of patients were studied to identify the major variables affecting statin use in this GC cohort. In addition to stratification by gender and age, analyses were stratified by the urban levels of NHI registration location, monthly insurance income, and some clinical comorbidities, which were the variables. Comorbidities included diabetes mellitus (ICD-9-CM codes 249--250), hypertension (ICD-9-CM codes 401--405), alcoholism (ICD-9-CM code 303), smoking-related disorders (ICD-9-CM codes 305.1, 491.2, 492.8, 496, 523.6, and V15.82), chronic kidney disease (ICD-9-CM code 585), and liver cirrhosis (ICD-9-CM codes 571.2, 571.5, and 571.6). Chemotherapy regimens (epirubicin-based, mitomycin-based, and taxanes) related to GC and exposure information of other medicine such as triglyceride-lowering drugs, non-statin lipid-lowering drugs, angiotensin-converting enzyme (ACE) inhibitors, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) were collected and identified as potential confounders in this study.

4.4. Propensity Score Matching {#sec4dot4-cancers-12-02055}
------------------------------

Propensity score (PS) matching was applied to reduce the confounding effects in the two groups \[[@B30-cancers-12-02055]\]. Thus, based on clinical variables comprising age, gender, level of urbanization, monthly insurance income, comorbidities, chemotherapy regimen, and other medicines mentioned above, we used PS to assess the probability of assigning patients as statin users to examine the effect of statin use. Statin users and statin non-users were matched by using PS at a ratio of 1:4.

4.5. Sensitivity Analyses {#sec4dot5-cancers-12-02055}
-------------------------

Sensitivity analysis was applied to assess the consistency between statin use and GC mortality. We performed analysis stratified by groups with and without the use of triglyceride-lowering drugs, non-statin lipid-lowering drugs, ACE inhibitors, aspirin, and NSAIDs; and the diseases of diabetes mellitus, hypertension, alcoholism, smoking-related disorder, chronic kidney disease, and liver cirrhosis. We also performed analysis stratified by gender and age from the date of surgery.

4.6. Statistical Analysis {#sec4dot6-cancers-12-02055}
-------------------------

Data analysis of descriptive statistics was performed to compare statin users with statin non-users stratified by patient demographics and comorbidities. We performed Pearson's chi-square test for categorical variables and *t*-test for continuous variables. The Kaplan--Meier method was used to appraise the accumulative probability of OS for statin users and non-users. We used the log-rank test to compare OS curves between the groups. The HRs with 95% CIs were computed using the Cox proportional hazard model adjusted for age, gender, urban level, monthly insurance income, comorbidities, chemotherapy regimen, and other medicines. A two-tailed *p* \< 0.05 indicated a significant difference. Data processing and analysis were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

5. Conclusions {#sec5-cancers-12-02055}
==============

Statin use may improve OS and reduce mortality in patients with GC after surgery and adjuvant chemotherapy in a dose-dependent manner. Further research must be conducted to improve the clinical evidence on the efficacy and safety of statin use in patients with GC.
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cancers-12-02055-t001_Table 1

###### 

Demographic characteristics of statin users and statin non-users among gastric cancer patients after surgery and adjuvant chemotherapy in Taiwan during 1999--2008 in the matched cohort.

  -----------------------------------------------------------------------------------------------------------
  Variables                                Statin Users\   Statin Non-Users\   *p*-Value \*          
                                           (*N* = 367)     (*N* = 1468)                              
  ---------------------------------------- --------------- ------------------- -------------- ------ --------
  **Gender**                                                                                         0.5543

  Female                                   159             43.3                611            41.6   

  Male                                     208             56.7                857            58.4   

  **Age at Surgery**                                                                                 0.4388

  18--64                                   172             46.9                655            44.6   

  ≥65                                      195             53.1                813            55.4   

  **Mean (SD)**                            64.3 (10.5)     64.1 (12.6)         0.758                 

  **Insured Salaries (NTD\$/month) ^a^**                                                             

  0+                                       70              19.1                277            18.9   

  1--15,840                                38              10.4                154            10.5   

  15,841--25,000                           185             50.4                733            49.9   

  \>25,000                                 74              20.2                304            20.7   

  **Urbanization Level**                                                                             0.5232

  Very High                                106             28.9                395            26.9   

  High                                     170             46.3                737            50.2   

  Moderate                                 62              16.9                241            16.4   

  Low                                      29              7.9                 95             6.5    

  **Comorbidities**                                                                                  

  Hypertension                             214             58.3                878            59.8   0.6009

  Diabetes Mellitus                        122             33.2                467            31.8   0.5996

  Alcoholism                               8               2.2                 23             1.6    0.4150

  Smoking-related disorder                 40              10.9                166            11.3   0.8244

  Chronic kidney disease                   13              3.5                 64             4.4    0.4848

  Liver cirrhosis                          14              3.8                 61             4.2    0.7682

  **Chemotherapy Regimen**                                                                           0.9425

  Group 1 (epirubicin-based)               29              7.9                 105            7.2    

  Group 2 (mitomycin-based)                49              13.4                205            14.0   

  Group 3 (taxanes)                        2               0.5                 10             0.7    

  Group 4 (others) ^b^                     287             78.2                1148           78.2   

  **Medication**                                                                                     

  **Triglyceride-Lowering Drugs**                                                                    0.0046

  User                                     19              5.2                 35             2.4    

  Non-user                                 348             94.8                1433           97.6   

  **Non-Statin Lipid-Lowering Drugs**                                                                0.4756

  User                                     8               2.2                 24             1.6    

  Non-user                                 359             97.8                1444           98.4   

  **ACE Inhibitors**                                                                                 0.9579

  User                                     98              26.7                390            26.6   

  Non-user                                 269             73.3                1078           73.4   

  **Aspirin**                                                                                        0.3669

  User                                     123             33.5                529            36.0   

  Non-user                                 244             66.5                939            64.0   

  **NSAID**                                                                                          0.7487

  User                                     291             79.3                1175           80.0   

  Non-user                                 76              20.7                293            20.0   

  **Death**                                138             37.6                895            61.0   
  -----------------------------------------------------------------------------------------------------------

\* Pearson's chi-square test for categorical variables and *t*-test for continuous variables. ^a^ 1 USD = 32.3 New Taiwan Dollars (NTD) in the year 2008. ^b^ Others: cisplatin, carboplatin, oxaliplatin, 5-FU (fluorouracil), capecitabine, TS-1 (tegafur/gimeracil/oteracil), and tegafur.

cancers-12-02055-t002_Table 2

###### 

Adjusted hazard ratios (HRs) of overall survival of gastric cancer patients after surgery and adjuvant chemotherapy associated with statin use after surgery during the follow-up period in the matched cohort.

  Variables                                      28--167 cDDD   ≥168 cDDD                                          
  ---------------------------------------------- -------------- ----------- ------ ---------- ------ ------ ------ ----------
  **Main Model \***                              **0.62**       0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  **Additional Covariates ^†^**                                                                                    
  Main model + Diabetes mellitus                 0.64           0.51        0.80   \<0.0001   0.33   0.25   0.44   \<0.0001
  Main model + Hypertension                      0.62           0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Alcoholism                        0.62           0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Smoking-related disorder          0.62           0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Chronic renal failure             0.62           0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Liver cirrhosis                   0.62           0.50        0.77   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Chemotherapy regimen              0.63           0.50        0.78   \<0.0001   0.33   0.25   0.44   \<0.0001
  Main model + Triglyceride-lowering drugs       0.62           0.50        0.78   \<0.0001   0.35   0.26   0.46   \<0.0001
  Main model + Non-statin lipid-lowering drugs   0.62           0.50        0.78   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + ACE inhibitors                    0.61           0.49        0.76   \<0.0001   0.34   0.26   0.45   \<0.0001
  Main model + Aspirin                           0.60           0.48        0.75   \<0.0001   0.33   0.25   0.44   \<0.0001
  Main model + NSAID                             0.60           0.48        0.75   \<0.0001   0.32   0.24   0.43   \<0.0001
  **Subgroup Effects**                                                                                             
  Sex                                                                                                              
  Male                                           0.76           0.57        1.02   0.0674     0.41   0.30   0.57   \<0.0001
  Female                                         0.49           0.35        0.70   \<0.0001   0.23   0.14   0.40   \<0.0001
  **Age at Surgery**                                                                                               
  18--64                                         0.46           0.31        0.67   \<0.0001   0.24   0.14   0.41   \<0.0001
  ≥65                                            0.75           0.57        0.99   0.0402     0.40   0.29   0.55   \<0.0001

\* Main model was adjusted for sex, age, urbanization, and income. ^†^ The models were adjusted for covariates in the main model as well as each additional listed covariate.
